(Q36150622)

12 August 2017

1 reference

title

Development of medications for alcohol use disorders: recent advances and ongoing challenges (English)

1 reference

12 August 2017

0 references

Raye Z Litten

1

1 reference

12 August 2017

Joanne Fertig

series ordinal

2

1 reference

12 August 2017

Margaret Mattson

series ordinal

3

1 reference

12 August 2017

Mark Egli

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

323-343

1 reference

12 August 2017

2

1 reference

The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Safety issues concerning the use of disulfiram in treating alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The clinical use of disulfiram (Antabuse): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Techniques to enhance compliance with disulfiram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Does disulfiram have a role in alcoholism treatment today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

What place does naltrexone have in the treatment of alcoholism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effects of naltrexone on alcohol self-administration in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Predicting treatment response to naltrexone: the influence of craving and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Potential neuroprotective effects of acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Alcohol effects during acamprosate treatment: a dose-response study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Implantable technology for long-term delivery of nalmefene for treatment of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Incomplete cross tolerance and multiple mu opioid peptide receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

GABA-ergic drugs: exit stage left, enter stage right

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A pilot trial of topiramate for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The use of divalproex in alcohol relapse prevention: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Add-on gabapentin in the treatment of opiate withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A summary of mechanistic hypotheses of gabapentin pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Ondansetron alters human alcohol intoxication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Ondansetron reduces the craving of biologically predisposed alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Antidepressant treatment of co-occurring depression and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effect of baclofen on alcohol and sucrose self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Baclofen for alcohol dependence: a preliminary open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The potential of dopamine agonists in drug addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Dopamine partial receptor agonists reduce ethanol intake in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Acute effects of memantine in combination with alcohol in moderate drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine decreases ethanol consumption via a protein kinase C epsilon-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The NMDA receptor partial agonist, 1-aminocyclopropanecarboxylic acid (ACPC), reduces ethanol consumption in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The endocannabinoid system: physiology and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Ethanol, endocannabinoids, and the cannabinoidergic signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Role of the endocannabinoid system in the development of tolerance to alcohol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The CRF1 receptor antagonist antalarmin reduces volitional ethanol consumption in isolation-reared fawn-hooded rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The therapeutic potential of CRF1 antagonists for anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A role for neuropeptide Y in alcohol intake control: evidence from human and animal research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Alcohol intake of P rats is regulated by muscarinic receptors in the pedunculopontine nucleus and VTA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Mecamylamine and ethanol preference in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Kudzu root: an ancient Chinese source of modern antidipsotropic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Daidzin, an antioxidant isoflavonoid, decreases blood alcohol levels and shortens sleep time induced by ethanol intoxication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Reduced operant ethanol self-administration and in vivo mesolimbic dopamine responses to ethanol in PKCepsilon-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Reduced ethanol withdrawal severity and altered withdrawal-induced c-fos expression in various brain regions of mice lacking protein kinase C-epsilon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Blockade of the leptin-sensitive pathway markedly reduces alcohol consumption in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Galanin microinjection in the third ventricle increases voluntary ethanol intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Overlapping peptide control of alcohol self-administration and feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Adenosine A1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Nitric oxide synthesis inhibition attenuates conditioned reinstatement of ethanol-seeking, but not the primary reinforcing effects of ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Neurokinin type-3 receptor stimulation impairs ethanol-associated appetitive behavior in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Mechanisms of the influences of the central administration of substance P on ethanol consumption in chronically alcoholic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Amlodipine, a calcium channel inhibitor, and cocaine and ethanol's reinforcing effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Neurobiological mechanisms in the transition from drug use to drug dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Location and nature of the residues important for ligand recognition in G-protein coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Rats on the grog: novel pharmacotherapies for alcohol craving.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Candidate genes for alcohol dependence: a review of genetic evidence from human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Association of GABRG3 with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Alcoholism: genes and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Barriers to the use of medications to treat alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Contemporary addiction treatment: a review of systems problems for adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Beliefs about evidence-based practices in addiction treatment: a survey of Veterans Administration program leaders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.323

10.1517/14728214.10.2.323

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference